Trial Profile
Valganciclovir for Suppression of HHV-8 Four Weeks Prior to Initiation of cART in Patients With Disseminated Kaposi Sarcoma Compare With Standard Therapy, Its Impact on the Development of IRIS and Attributable Mortality
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary) ; Antiretrovirals
- Indications Acquired immunodeficiency syndrome; HIV infections; Immune reconstitution syndrome; Kaposi's sarcoma; Lymphoedema
- Focus Therapeutic Use
- 07 Feb 2024 Results assessing the proinflammatory axis tumor necrosis factor (TNF) and its receptors (TNFRs) in T cells, published in the Clinical and Experimental Immunology.
- 11 Mar 2020 Results evaluating Impact of Valganciclovir Therapy on Severe IRIS-KAPOSI Sarcoma Attributable Mortality, presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 13 Mar 2019 Planned End Date changed from 1 Oct 2018 to 10 Aug 2019.